American Portfolios Advisors’s Ascendis Pharma A/S ASND Stock Holding History

American Portfolios Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1	Closed	-$139	–	2782
2019 Q4	$139	Hold	1	–	–	﹤0.01%	2789
2019 Q3	$96	Buy	+1	New	+$112	﹤0.01%	2786

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

American Portfolios Advisors's ASND Position: Q1 2020 in Review

American Portfolios Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2020, closing a stake of 1 share — an estimated $139 sold.

American Portfolios Advisors first reported a position in ASND in Q3 2019 and held it in 2 quarters. The position peaked at $139 in Q4 2019. 147 funds tracked by Wall St. Rank hold ASND as of Q1 2020.

American Portfolios Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2020 after selling out during the quarter.
American Portfolios Advisors sold 1 Ascendis Pharma A/S share in Q1 2020, an estimated $139.
American Portfolios Advisors first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 2 quarters.
American Portfolios Advisors's Ascendis Pharma A/S position peaked at $139 in Q4 2019.
147 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2020.

Based on American Portfolios Advisors's 13F filing for Q1 2020, filed 24 Mar 2023.